You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

GADOTERATE MEGLUMINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Gadoterate Meglumine patents expire, and what generic alternatives are available?

Gadoterate Meglumine is a drug marketed by Hainan Poly and Hengrui Pharma and is included in two NDAs.

The generic ingredient in GADOTERATE MEGLUMINE is gadoterate meglumine. Four suppliers are listed for this compound. Additional details are available on the gadoterate meglumine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Gadoterate Meglumine

A generic version of GADOTERATE MEGLUMINE was approved as gadoterate meglumine by HENGRUI PHARMA on April 11th, 2022.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GADOTERATE MEGLUMINE?
  • What are the global sales for GADOTERATE MEGLUMINE?
  • What is Average Wholesale Price for GADOTERATE MEGLUMINE?
Summary for GADOTERATE MEGLUMINE
Drug patent expirations by year for GADOTERATE MEGLUMINE
Recent Clinical Trials for GADOTERATE MEGLUMINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
BayerPhase 3
Boehringer IngelheimPhase 2
Massachusetts General HospitalPhase 2

See all GADOTERATE MEGLUMINE clinical trials

Pharmacology for GADOTERATE MEGLUMINE

US Patents and Regulatory Information for GADOTERATE MEGLUMINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hainan Poly GADOTERATE MEGLUMINE gadoterate meglumine SOLUTION;INTRAVENOUS 218073-001 Jun 17, 2024 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hengrui Pharma GADOTERATE MEGLUMINE gadoterate meglumine SOLUTION;INTRAVENOUS 215304-002 Apr 11, 2022 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hainan Poly GADOTERATE MEGLUMINE gadoterate meglumine SOLUTION;INTRAVENOUS 218073-004 Jun 17, 2024 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hengrui Pharma GADOTERATE MEGLUMINE gadoterate meglumine SOLUTION;INTRAVENOUS 215304-003 Apr 11, 2022 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.